Natco Pharma launches low cost Semaglutide as India GLP one market opens after patent expiry
Natco Pharma has moved swiftly to launch a generic version of Semaglutide in India on the first day of patent expiry, positioning itself as an early leader in the fast-growing GLP-1 therapy market. The aggressive pricing strategy signals a potential disruption in diabetes treatment access and competitive dynamics within the domestic pharma sector.
By Finblage Editorial Desk
11:35 am
20 March 2026
In a significant development for India’s pharmaceutical landscape, Natco Pharma has announced the commercial launch of generic Semaglutide injection in the domestic market, coinciding with the expiry of Novo Nordisk’s patent on the drug. The move marks one of the earliest entries into what is widely regarded as a high-growth therapeutic segment, particularly for diabetes and metabolic disorders.
According to the company’s disclosure, Natco received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market generic Semaglutide following a clinical comparison study. The product will be introduced initially in multi-dose vial formats across three strengths, with a pen device format expected to follow in April 2026.
Semaglutide belongs to the GLP-1 receptor agonist class, a category that has seen strong global demand due to its efficacy in managing type 2 diabetes and its emerging role in weight management therapies. With India witnessing a rising burden of diabetes, the availability of cost-effective alternatives could significantly alter treatment penetration.
Natco’s pricing strategy appears central to its market entry. The company has priced its multi-dose vials at around Rs 1,290 per month for lower strengths and Rs 1,750 for higher dosage, positioning them at a steep discount compared to existing branded therapies. The pen devices, while priced higher, still remain significantly below innovator pricing. The company claims its offering is approximately 70 percent cheaper than comparable pen devices and nearly 90 percent lower than the innovator’s brand.
This sharp pricing differential is likely to expand patient access, especially in a cost-sensitive market like India where long-term therapy adherence is often constrained by affordability. By offering multi-dose vials with customised syringes, Natco is also introducing a differentiated delivery mechanism that could appeal to both patients and healthcare providers.
Importantly, the company has indicated that it will also open up the product for co-marketing partnerships, suggesting a strategy to scale distribution rapidly without relying solely on its own sales infrastructure. This could accelerate adoption across both urban and semi-urban markets.
The broader market reaction has been measured but positive. Natco Pharma shares were trading around 2.5–2.6 percent higher intraday, reflecting investor optimism around the company’s first-mover advantage. Meanwhile, shares of Dr Reddy's Laboratories and Emcure Pharma also saw modest gains, as investors anticipate broader participation from Indian players in the post-patent GLP-1 opportunity.
From a sectoral standpoint, this development signals the opening of a new competitive phase in India’s anti-diabetic drug market. The entry of generics is expected to intensify pricing pressure on innovator products while simultaneously expanding the overall market size through improved affordability.
For the Indian pharmaceutical sector, the launch underscores a structural shift toward complex generics and specialty therapies. Unlike traditional generics, GLP-1 drugs involve more complex manufacturing and regulatory pathways, suggesting that only a limited number of players may be able to compete effectively in the near term.
Sources & Disclaimer
This article is compiled from publicly available information, including company disclosures, stock exchange filings, regulatory announcements, and reports from global and domestic financial publications. The content has been editorially reviewed and enhanced by the Finblage Editorial Desk for clarity and investor awareness purposes only.
All information provided on Finblage is strictly for educational and informational use and should not be considered as financial, investment, legal, or professional advice. Readers are advised to conduct their own independent research and consult a certified financial advisor before making any investment decisions. Finblage shall not be held responsible for any losses arising from the use of information published on this website.
Premium Edition

Insights > JSW Cement
Can Margin Expansion and Green Cement Leadership Drive a Long-Term Re-Rating ?
JSW Cement delivered one of its strongest quarterly performances in Q4 FY26, driven by sharp EBITDA expansion, improving operational efficiency, stronger unit economics, and strategic capacity expansion in North India. The company’s focus on cost optimisation, green energy integration, and leadership in the GGBS segment is increasingly positioning it as a differentiated player within India’s fast-consolidating cement industry.
28 May 2026
_edited.png)


